Navigation Links
Optetrak Cruciate Sparing Knee

ProductsOptetrak Cruciate Sparing Knee
Company Exactech, Inc.
Item Optetrak Cruciate Sparing Knee
Features Incorporation of a deeper patellar groove and softening the component edges where contact between prosthesis and retinacular tissue occurs, Optetrak has minimized stretch of the retinacular tissues and decreased the possibility that a lateral release of those tissues will be needed.
Description The Optetrak system includes a cruciate sparing version which provides the following: Patellar flange mates with both resurfacing and inset patellas. Precision machined condyles assure precise, repeatable kinematics and fit with tibial articular surface and patella to reduce wear. Constant cutting guide peg locations provide easy intraoperative change of sizes. Extended and deepened patellar groove reduces shear and compressive stress on patellar component. Less prominent femoral flange edges reduce surrounding soft tissue tension and improve patellar tracking. Unlike other implants, Optetrak is fully machined on the under surface for better implant-to-bone fit.
Info Exactech, Inc.
Customer Service: (800) 392-2832
Web site: http://www.exac.com

Related medicine products :

1. Optetrak Posterior stabilized Knee
2. Optetrak Cruciate Retaining
3. Optetrak Posterior Stabilized
4. Proven Cruciate Retaining Knee System, standard
5. Proven Cruciate Retaining Knee System, curved
6. TC-Plus Solution, PE insert (Cruciate retaining)
7. TC-Plus Solution, PE insert (Cruciate Substituting)
8. TC-Plus Solution, PE insert (Cruciate substituting - ultracongruent)
9. Proven Cruciate Retaining Knee System
10. The Comprehensive Natural-Knee Cruciate Retaining System
11. NexGen Complete Knee Solution Cruciate Retaining (CR)
The Shandon Manual Staining Station is ideal for special processes, frozen sections, special stains and low volume procedures.
The Shandon Finesse 315 low-cost precision microtome is ergonomically designed to consistently produce high quality routine paraffin sections without user strain or fatigue.
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor.
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains.
Medicine Products:
(Date:5/16/2008)... AIDS Vaccine is Possible and,Still Urgently Neede...Twenty-five years since the,discovery of HIV, the ...,the AIDS pandemic. Scientists have learned a trem...er pathogen, and have developed more drugs to,trea... this progress is not,enough. While it is vital to...
(Date:5/16/2008)...ewswire/ -- Less than a week after,committing medi...tated by,Cyclone Nargis, Project HOPE, an internat... organization, is again mobilizing its full,resour...r the people of,central China devastated by the ma...ves., "I am saddened by the vast loss of life and...
(Date:5/16/2008)... abstracts or poster presentations at the annual m...y (ASCO) to be held in Chicago, Illinois, May 30 ...arly Detection of Malignant Pleural Mesothelioma ...ly detection and prognostic marker,in malignant p... Pass, M.D., professor of cardiothoracic surgery a...
(Date:5/16/2008)...wire/ -- Behavioral healthcare,systems are playing...llions,of Americans of all ages who experience psy...ccording to the latest annual survey from the,Nati...PHS) released today., The 2007 NAPHS Annual Surve...care delivery. One chapter provides a trend analys...
Breaking Medicine News(10 mins):Health News:World AIDS Vaccine Day 2008 2Health News:World AIDS Vaccine Day 2008 3Health News:World AIDS Vaccine Day 2008 4Health News:Project HOPE to Send Humanitarian Assistance to China as Humanitarian Assistance to Myanmar Continues 2Health News:NYU Langone Medical Center's tip sheet to the 44th annual meeting of ASCO 2Health News:NYU Langone Medical Center's tip sheet to the 44th annual meeting of ASCO 3Health News:NYU Langone Medical Center's tip sheet to the 44th annual meeting of ASCO 4Health News:New NAPHS Annual Survey Tracks Behavioral Treatment Trends 2
...chers are conducting a study to find out ways to i...eople. // Pfizer Australia Cardio Vascular Lipid (...r Clair Sullivan from the Centre for Diabetes and ... Queensland and Princess Alexandra Hospital for th...
...t difference found with respect to major clinical ...ng C-section. Some women, however had lower blood...ral anesthesia and some experienced more nausea an...This was the first such review to consider both ne...
...main culprit for nerve fibre damage in multiple sc...ne system, which is vital for early diagnosis // a.... The study indicated the manner in which immune s...tacks by hampering the energy production in nerve ...
...emonstrated how intense struggle among the human i...us to survive harm and take on a more virulent for... The study, which uses a computer model of simulta...es a hint of a new strategy for using vaccines aga...
Other Medicine News:Health News:Choice of Anesthesia in C-section 2Health News:Choice of Anesthesia in C-section 3Health News:Basis for Nerve fiber Damage in Multiple Sclerosis Discovered 2Health News:Basis for Nerve fiber Damage in Multiple Sclerosis Discovered 3Health News:HIV Takes Advantage of Rivalry among T cells 2Health News:HIV Takes Advantage of Rivalry among T cells 3
(Date:5/16/2008)...sults demonstrating that TYKERB and trastuzumab to...on of progression-free survival (PFS), -- Combini...e and,outside of the HER2 receptor may create a mo...activity of TYKERB alone despite patients,previou... chemotherapy, LONDON and PHILADELPHIA, May 16 /P...
(Date:5/16/2008)...tically Significant Reductions in Selected ...to be published in 2008 Proceedings of the America...cology, SAN DIEGO, May 16 /PRNewswire-FirstCall/ ...nounced today that, in a registrational bioequival...tically significant reduction,in general disorders...
(Date:5/15/2008)...ta highlight safety profile of BSI-201 in ...ISBANE, Calif., May 15 /- BiPar Scien...any developing novel cancer therapies,today annou... BSI-201, will,be presented at the 2008 American S...ago., Findings will be presented from the first i...
(Date:5/15/2008)...RNewswire-FirstCall/ -- Schering-Plough,Corporatio... and treatment of,chronic hepatitis C virus (HCV) ...clinical studies with PEGINTRON(TM) (peginterferon...ion therapy, as well as boceprevir, the,company,s ...be presented at,the 39th annual Digestive Disease ...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Baltimore Washington Medical Center Hosts Day of Dance for Health 10732 1Baltimore Washington Medical Center Hosts Day of Dance for Health 10732 2Study finds widespread vitamin and mineral use among cancer survivors 10729 1Study finds widespread vitamin and mineral use among cancer survivors 10729 2Unilens Vision Inc Declares Regular Quarterly Cash Dividend of U S 240 09 Per Share 10722 1Unilens Vision Inc Declares Regular Quarterly Cash Dividend of U S 240 09 Per Share 10722 2Unintended Errors Leave Many Newborns Vulnerable 10721 1Unintended Errors Leave Many Newborns Vulnerable 10721 2
... be published in an upcoming issue of,Anti-Cancer ...rapeutics Inc.,(TSX-V:PRX) today announced that tw... PRX 302. The Journal of the National Cancer,Insti...Dr. Sam,Denmeade and his team at Johns Hopkins Uni...he paper describes the Company,s compound,PRX302,...
...IFICANT CORRELATION BETWEEN,PLASMA LEVELS AND CLIN...t will host a conference call and live,webcast on ...f. (March 19, 2007) – Corcept Therapeutics,I...tudy 06, the,last of three Phase 3 trials evaluati...sychotic Major Depression (PMD), did not,achieve s...
Other Medicine Technology:Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases 2Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases 3Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint 2Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint 3Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint 4Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint 5